A day in the life of a retinal specialist… Costantino John Trombetta

Article

A day in the life of a retinal specialist

Next page

Where I work

Allow me to introduce myself; my name is Costantino John Trombetta and I am a medical and surgical vitreoretinal consultant based in the Ophthalmology department at the University of Messina.

Messina is a medium-sized city with approximately 250,000 inhabitants. Geographically, it is situated at the North-East tip of Sicily, just in front of the coasts of Calabria - the southernmost point of the Italian peninsula. A stretch of just three nautical miles, which is served by a very intense traffic of ferries, separates the two coasts. The two sides of the coast can in fact be considered as part of one single geographical region: the area of the straits of Messina, which in total contains more than half a million inhabitants. The economic status is very different on both sides, with the Sicilian part being wealthier. Messina has a long-standing tradition in ophthalmic care and, as such, our department attracts large numbers of patients from all over Sicily and nearby Calabria.

Organising the clinic

One consultant (me), one clinical assistant, three part-time young ophthalmologists, two residents, and one nurse represent our total staff.

Our working day is approximately six hours, starting at 8.00 am and, once clinic has ended, I commence my private practice, which begins at 3.00 pm.

The clinic is divided into three large rooms, with a waiting room, and is in close proximity to the operating theatre.

In terms of our imaging and diagnostics equipment, we currently use a Heidelberg HRA angiograph (Heidelberg Engineering) and a Stratus OCT 3 (Carl Zeiss Meditec). Meanwhile, for treatments we use a Zeiss Visulas thermal laser and a Zeiss infrared laser for photodynamic therapy (PDT) (Carl Zeiss Meditec). The operating theatre is equipped for all aspects of ophthalmic surgery, and we use a small surgical sterile room to administer intravitreal injections.

Next page

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.